A 75-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer

Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Treatment with enzalutamide alone and with leuprolide delivered higher rates of undetectable PSA levels compared with leuprolide alone in patients with castration-sensitive prostate cancer.

A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.

Data support using 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

Administering high-intensity focused ultrasound could be a noninferior treatment option for patients with localized prostate cancer, according to a prospective trial.